NITROMED SHARES PLUNGE ON SOFT DRUG SALES

Shares of NitroMed Inc. tumbled 31 percent Tuesday after the pharmaceutical maker said sales of its heart-failure drug, approved for use only by blacks, again fell short of expectations. NitroMed also said it expects net sales of the 10-month-old drug BiDil will amount to $20 million this year, less than half of the $44 million consensus estimate of analysts surveyed by Thomson Financial.
Westfall Weekly News